Skip to main content
OpenTrials
Completed

NCT Number: NCT01472497

Effects of Pioglitazone in Hypertensive Patients

Insulin resistance is often complicated with hypertension. AGE and inflammation play important roles in insulin resistance. Some studies reported that pioglitazone, insulin sensitizer, is effective for patients with insulin resistance, however, the mechanisms are still unclear. The aim of this study to evaluate the effect of pioglitazone compared with glimepiride on AGE, inflammatory cytokines and cardiac markers (BNP and echo) in hypertensive patients during oral glucose tolerance test.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Glucose Metabolism Disorders Hyperinsulinism Insulin Resistance Metabolic Diseases Nutritional and Metabolic Diseases Vascular Diseases

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Tottori University Hospital

Yonago, 683-8504, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hypertension with insulin resistance

Exclusion criteria

  • Chronic systolic heart failure, ACS

Treatment and study plan

pioglitazone

Drug

pioglitazone (15mg) once a day for 24 weeks

Other names: actos

Primary outcomes

  1. advanced glycation end-product (AGE)

    Time frame: 24 weeks

  2. inflammatory cytokines (TNF-alfa, IL-6 and MCP-1)

    Time frame: 24 weeks

  3. cardiac function (echo and BNP)

    Time frame: 24 weeks

Sponsors and collaborators

Lead sponsor

Tottori University Hospital

Other

Registry information

Official study title

Effects of Pioglitazone and Glimepiride in Hypertensive Patients - Relationship With AGE, Inflammatory Cytokines and Cardiac Markers -

Important dates

Study start
2007
Primary completion
2011
Study completion
2012
First posted
Nov 16, 2011
Registry last updated
Jun 5, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.